Beijing Minhai Biotechnology Co Ltd - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Beijing Minhai Biotechnology Co Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Beijing Minhai Biotechnology Co Ltd - Product Pipeline Review - 2016', provides an overview of the Beijing Minhai Biotechnology Co Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Beijing Minhai Biotechnology Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Beijing Minhai Biotechnology Co Ltd
- The report provides overview of Beijing Minhai Biotechnology Co Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Beijing Minhai Biotechnology Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Beijing Minhai Biotechnology Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Beijing Minhai Biotechnology Co Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Beijing Minhai Biotechnology Co Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Beijing Minhai Biotechnology Co Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Beijing Minhai Biotechnology Co Ltd Snapshot 7
Beijing Minhai Biotechnology Co Ltd Overview 7
Key Facts 7
Beijing Minhai Biotechnology Co Ltd - Research and Development Overview 8
Key Therapeutic Areas 8
Beijing Minhai Biotechnology Co Ltd - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Beijing Minhai Biotechnology Co Ltd - Pipeline Products Glance 16
Beijing Minhai Biotechnology Co Ltd - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Beijing Minhai Biotechnology Co Ltd - Clinical Stage Pipeline Products 18
Phase I Products/Combination Treatment Modalities 18
Beijing Minhai Biotechnology Co Ltd - Early Stage Pipeline Products 19
IND/CTA Filed Products/Combination Treatment Modalities 19
Preclinical Products/Combination Treatment Modalities 20
Beijing Minhai Biotechnology Co Ltd - Drug Profiles 21
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
(hepatitis A + hepatitis B) vaccine - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
(measles + rubella + varicella) vaccine - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
cholera (trivalent) vaccine - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Enterovirus [serotype EV-A71] vaccine - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Haemophilus influenzae B vaccine - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
hepatitis A vaccine - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
hepatitis B vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
herpes simplex virus vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
herpes zoster vaccine - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
human papillomavirus (quadrivalent) vaccine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
influenza (split virion) vaccine - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
influenza [strain A/H1N1] vaccine - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
influenza [strain A/H7N9] vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
meningococcal [serotype B] vaccine - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
mumps vaccine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
pneumococcal (13-valent) vaccine - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
pneumococcal (23-valent) vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
rabies vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
rotavirus (pentavalent) vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
varicella zoster vaccine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Beijing Minhai Biotechnology Co Ltd - Pipeline Analysis 45
Beijing Minhai Biotechnology Co Ltd - Pipeline Products by Route of Administration 45
Beijing Minhai Biotechnology Co Ltd - Pipeline Products by Molecule Type 46
Beijing Minhai Biotechnology Co Ltd - Dormant Projects 47
Beijing Minhai Biotechnology Co Ltd - Locations And Subsidiaries 48
Head Office 48

Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables

Beijing Minhai Biotechnology Co Ltd, Key Facts 7
Beijing Minhai Biotechnology Co Ltd - Pipeline by Indication, 2016 9
Beijing Minhai Biotechnology Co Ltd - Pipeline by Stage of Development, 2016 11
Beijing Minhai Biotechnology Co Ltd - Monotherapy Products in Pipeline, 2016 12
Beijing Minhai Biotechnology Co Ltd - Combination Treatment Modalities in Pipeline, 2016 13
Beijing Minhai Biotechnology Co Ltd - Partnered Products in Pipeline, 2016 14
Beijing Minhai Biotechnology Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 15
Beijing Minhai Biotechnology Co Ltd - Pre-Registration, 2016 16
Beijing Minhai Biotechnology Co Ltd - Phase III, 2016 17
Beijing Minhai Biotechnology Co Ltd - Phase I, 2016 18
Beijing Minhai Biotechnology Co Ltd - IND/CTA Filed, 2016 19
Beijing Minhai Biotechnology Co Ltd - Preclinical, 2016 20
Beijing Minhai Biotechnology Co Ltd - Pipeline by Route of Administration, 2016 45
Beijing Minhai Biotechnology Co Ltd - Pipeline by Molecule Type, 2016 46
Beijing Minhai Biotechnology Co Ltd - Dormant Developmental Projects,2016 47